Nonmajor histocompatibility complex alloantigen effects on the fate of Rous sarcomas
Rous sarcoma virus-induced tumor outcome is controlled by the MHC (B). Additional data, using controlled segregation in families, has indicated non-MHC effects as well, but few studies have focused on blood groups other than the B complex. Segregating combinations of genes encoding erythocyte (Ea) alloantigen systems A, C, D, E, H, I, P, and L in (BB5)-B-2 and (BB5)-B-5 MHC (B) backgrounds were examined for their effects on Rous sarcomas. Six-week-old chickens were inoculated in the wing-web with 30 pfu of Rous sarcoma virus (RSV). Tumors were scored six times over a 10-wk period. A tumor profile index (TPI) was assigned to each chicken based on the six tumor size scores. Response was evaluated using tumor size at each measurement period, TPI, and mortality. The genotypes of Ea systems A, C, D, E, H, I, and P had no significant effect on any parameter in either B complex population. The Ea-L system had an effect on Rous sarcomas in the (BB5)-B-2 intermediate responders and B5B5 progressors. Tumor size, TPI, and mortality were all significantly lower in (BB5)-B-2 (LL1)-L-1 chickens than in (BB5)-B-2 (LL2)-L-1 chickens. Mortality was lower in the (BB5)-B-5 (LL1)-L-1 birds than in (BB5)-B-5 (LL2)-L-1 chickens. It appears that the Ea-L system, or one closely linked, is acting in a manner independent of the B complex in response to RSV challenge.
Poultry Science Association
Scientific Contribution Number
Lepage, K. T.; Briles, W. E.; Kopti, F.; and Taylor, R. L. Jr., "Nonmajor histocompatibility complex alloantigen effects on the fate of Rous sarcomas" (2000). Poultry science. 178.
© 2000 Poultry Science Association Inc.